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Abstract
In our recent studies, we identified compound N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) as a broad-spectrum hybrid
anticonvulsant which showed potent protection across the most important animal acute seizure models such as the maximal electro-
shock (MES) test, the subcutaneous pentylenetetrazole (s.c. PTZ) test, and the 6-Hz (32 mA) test in mice. Therefore, AS-1 may be
recognized as a candidate for new anticonvulsant effective in different types of human epilepsy with a favorable safety margin profile
determined in the rotarod test in mice. In the aim of further pharmacological evaluation of AS-1, in the current study, we examined its
activity in the 6-Hz (44 mA) test, which is known as the model of drug-resistant epilepsy. Furthermore, we determined also the
antiseizure activity in the kindling model of epilepsy induced by repeated injection of pentylenetetrazole (PTZ) in mice. As a result,
AS-1 revealed relatively potent protection in the 6-Hz (44 mA) test, as well as delayed the progression of kindling induced by repeated
injection of PTZ in mice at doses of 15 mg/kg, 30 mg/kg, and 60 mg/kg. Importantly, the isobolographic analysis showed that a
combination of AS-1 and valproic acid (VPA) at the fixed ratio of 1:1 displayed a supra-additive (synergistic) interaction against PTZ-
induced seizures inmice. Thus, AS-1may be potentially used in an add-on therapywith VPA.Moreover, incubation of zebrafish larvae
with AS-1 substantially decreased the number, cumulative but not the mean duration of epileptiform-like events in electroencephalo-
graphic assay. Finally, the in vitro ADME-Tox studies revealed that AS-1 is characterized by a very good permeability in the parallel
artificial membrane permeability assay test, excellent metabolic stability on human liver microsomes (HLMs), no significant influence
onCYP3A4/CYP2D6 activity, andmoderate inhibition of CYP2C9 in a concentration of 10μM, aswell as no hepatotoxic properties in
HepG2 cells (concentration of 10 μM).
* Katarzyna Socała
ksocala@op.pl
1 Jagiellonian University Medical College, Faculty of Pharmacy,
Department of Medicinal Chemistry, Medyczna 9,
30-688 Cracow, Poland
2 Department of Animal Physiology, Institute of Biology and
Biochemistry, Faculty of Biology and Biotechnology, Maria
Curie-Skłodowska University, Akademicka 19,
20-033 Lublin, Poland
3 Isobolographic Analysis Laboratory, Institute of Rural Health,
Jaczewskiego 2, 20-090 Lublin, Poland
4 Jagiellonian University Medical College, Faculty of Pharmacy,
Department of Pharmacodynamics, Medyczna 9,
30-688 Cracow, Poland
5 Chemical Neuroscience Group, Centre for Molecular Medicine
Norway, University of Oslo, Gaustadalléen 21, Forskningsparken,
0349 Oslo, Norway
6 Department of Experimental and Clinical Pharmacology, Medical
University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland
7 Jagiellonian University Medical College, Faculty of Pharmacy,
Department of Technology and Biotechnology of Drugs, Medyczna
9, 30-688 Cracow, Poland
8 Department of Drug Technology and Pharmaceutical Biotechnology,
Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
9 Laboratory of Physiology and Pathophysiology, Centre for
Preclinical Research and Technology,Medical University ofWarsaw,
Banacha 1B, 02-097 Warsaw, Poland
10 Department of Pathophysiology, Medical University of Lublin,
Jaczewskiego 8b, 20-090 Lublin, Poland
https://doi.org/10.1007/s13311-019-00773-w
Published online: 4 September 2019
Neurotherapeutics (2020) 17:309–328
Key Words Drug-resistant epilepsy . PTZ-kindling model of epilepsy . isobolographic studies . electrophysiology . ADME-Tox
properties . zebrafish
Introduction
Epilepsy, which affects about 1% of the world population, be-
longs to the most common, heterogeneous, and debilitating neu-
rological diseases with a high risk of drug resistance [1].
According to the International League Against Epilepsy, the
current classification of seizure types distinguishes three major
groups, as follows: generalized-onset seizures (with retained or
impaired awareness), focal-onset seizures, and unknown-onset
seizures [2]. Due tomultifactorial pathomechanism and different
clinical manifestations of epilepsy, about 30% of patients do not
successfully respond to pharmacotherapy and are considered to
have drug-resistant epilepsy (DRE) [3]. The refractory epilepsy
usually requires the application of two or three various antiepi-
leptic drugs (AEDs), preferentially with different mechanisms of
action. Unfortunately, this therapeutic regimen increases the risk
of drug–drug interactions (DDIs), and may also lead to potenti-
ation of side effect and, finally, to discontinuation of the treat-
ment. Patients suffering from uncontrolled seizures are prone to
numerous and serious psychiatric conditions such as depression,
cognitive impairment, or anxiety [4, 5]. Furthermore, current
pharmacotherapy is only symptomatic, as the available AEDs
inhibit seizures but these medications are devoid of
antiepileptogenic, as well as disease-modifying properties. As
a result, both old- and new-generation AEDs do not cure epi-
lepsy and therefore cannot be used as prophylaxis especially
of idiopathic disease. Bearing in mind the aforementioned facts,
the search for new AEDs is still hugely necessary and should be
directed on broad-spectrum anticonvulsants, preferentially with
complex mechanisms of action and favorably with
antiepileptogenic and/or disease-modifying properties [6, 7].
With the aim of obtaining new and effective anticonvulsants,
since many years, our efforts have been focused on the devel-
opment of hybrid compounds based on the pyrrolidine-2,5-
dione core fragment [8–14]. It should be stressed that in recent
years, the hybrid substances are of great importance in designing
of multitargeted compounds, as they have been proven to be
advantageous in the treatment of multifactorial diseases and also
have been proven to alleviate health conditions linked to drug
resistance [15, 16]. Epilepsy without any doubt fulfills both the
aforementioned criteria. Multitargeted compounds, proposed by
our team, were designed as integrated hybrids which combine
structural fragments of known and therapeutically relevant
AEDs, such as ethosuximide (ETX, pyrrolidine-2,5-dione deriv-
ative), levetiracetam (LEV, pyrrolidin-2-one derivative), and
lacosamide (LCS, classified as functionalized amino acid). The
applied molecular hybridization yielded compounds with potent
and wide anticonvulsant properties in the preclinical studies, as
they were effective in the maximal electroshock (MES) seizure
test, the 6-Hz (32 mA) seizure model, and the subcutaneous
pentylenetetrazole (s.c. PTZ) seizure model [8–14].
Importantly, compounds with the aforementioned profile in the
in vivo studies may be effective in the pharmacotherapy of a
wide range of human epilepsies including tonic–clonic seizures
(with or without secondary generalization), absence epilepsy, as
well as myoclonic and partial seizures. Furthermore, the results
proved the success of proposed molecular hybridization, as our
compounds revealed wider anticonvulsant activity than each
individual AED, which creates hybrid structure as follows:
ETX (s.c. PTZ active), LEV (6-Hz, 32 mA active), and LCS
(effective in the MES and 6-Hz (32 mA) models). Among the
obtained substances, the favorable pharmacological and toxico-
logical profile was observed for N-benzyl-2-(2,5-
dioxopyrrolidin-1-yl)propanamide (AS-1), which was identified
as one of the lead compounds (Fig. 1).
The preclinical data for AS-1 (Fig. 1) revealed more potent
protection in each seizure model (MES, s.c. PTZ, 6-Hz) and
simultaneously distinctly more pronounced separation be-
tween anticonvulsant and neurotoxic doses compared to
valproic acid (VPA), which was tested in the same experimen-
tal conditions as follows: median effective dose (ED50;
MES) = 252.74 mg/kg, ED50 (s.c. PTZ) = 239.45 mg/kg,
ED50 (6-Hz, 32 mA) = 130.65 mg/kg, and TD50 (rotarod
test) = 430.77 mg/kg (data in mice injected intraperitoneally
(i.p.) from [10, 12]). It is noteworthy, despite of implementa-
tion to pharmacotherapy many new AEDs, VPA is still recog-
nized as the clinically relevant wide-spectrum AEDwith com-
plex mechanisms of action and a wide range of indications in
different types of human epilepsy.
The mouse 6-Hz model applying the 44 mA stimulus in-
tensity has been identified as a useful tool in the identification
of novel compounds with potential efficacy against drug-
resistant epilepsy [17, 18]. Thus, in the current studies, AS-1
was screened in the 6-Hz (44 mA) test. Furthermore, taking
into consideration the favorable activity of AS-1 in the acute
models of seizures, we have determined herein its protective
properties in the pentylenetetrazole (PTZ)-induced chemical
kindling model. In this chronic model of epilepsy, repeated
injection of PTZ evokes progressive enhancement of seizure
susceptibility [19]. Moreover, the effects of repeated treatment
with AS-1 on kindling-associated behavioral despair and anx-
iety were evaluated. Using the timed intravenous (i.v.) PTZ
seizure threshold model, we determined the changes in seizure
susceptibility following PTZ kindling. In addition, acute ef-
fects of AS-1 on seizure threshold in naïve animals were also
investigated.
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In the last few years, we can observe a tendency to study
potential and clinically beneficial DDIs, mainly due to resis-
tance to one drug treatment (i.e., in case of refractory epilep-
sy). It turns out that two or more drugs given in combination
may produce effect more potent or weaker than that observed
for individual agents. Therefore, much is being done to find
the most favored combinations. It should be stressed here the
treatment with more than one drug may cause more side ef-
fects as well. Isobolographic analysis is a method enabling
assessment of the interaction between drugs and allows their
classification as supra-additive (synergistic), additive, sub-
additive (antagonistic), and indifferent (neutral) [20–22].
Based on the results obtained from our previous studies indi-
cating marked anticonvulsant properties of AS-1 in various
animal models of seizures [10, 12], we decided to determine
the interaction between AS-1 and one of the most common
classic AEDs—VPA, using isobolographic analysis in the
PTZ model of seizures. Additionally, we evaluated the impact
of the AS-1 + VPA combination on the motor coordination,
muscular strength, and long-term memory in mice. We also
investigated the effect of 24 h-long incubation with AS-1 on
the number and duration of electroencephalographic (EEG)
epileptiform-like discharges induced by acute PTZ adminis-
tration in 7-day post-fertilization zebrafish larvae.
In the present study, we also attempted to discuss the mech-
anism of action of AS-1, which remains unknown. Finally,
bearing in mind drug-like properties of AS-1, several
ADME-Tox parameters were determined in in vitro assays.
Material and Methods
Compounds
AS-1 was obtained in the Department of Medicinal
Chemistry, Jagiellonian University Medical College, accord-
ing to the procedures described elsewhere [10]. The reference
AED sodium valproate (VPA) and pentylenetetrazole (PTZ)
were purchased from a commercial supplier (Sigma-Aldrich,
St. Louis, MO). Before in vivo and in vitro studies, AS-1 was
fully characterized using the spectral (1H NMR, 13C NMR)
and elemental (C, H, N) analyses. The purity and homogene-
ity of the compounds were assessed by thin-layer chromatog-
raphy (TLC) and the gradient ultra-performance liquid chro-
matography (UPLC). TLC was performed on silica gel 60
F254 precoated aluminum sheets (Macherey-Nagel, Düren,
Germany), using the following developing system: dichloro-
methane/methanol, 9:0.3 (v/v). A spot was detected by its
absorption under UV light (λ = 254 nm). The UPLC analysis
and mass spectra (LC-MS) were obtained on Waters
ACQUITY TQD system (Waters, Milford, CT) with the
MS-TQ detector and UV-vis-DAD eλ detector. The
ACQUITYUPLC BEHC18 1.7-μm (2.1 mm × 100 mm) col-
umn was used with the VanGuard ACQUITY UPLC BEH
C18, 1.7 μm (2.1 × 5 mm) (Waters). Standard solutions
(1 mg/ml) were prepared in analytical grade MeCN/water
mixture (1:1; v/v). Conditions applied were as follows: eluent
A (water/0.1% HCOOH), eluent B (MeCN/0.1% HCOOH), a
Fig. 1 Molecular hybridization which yielded the compound AS-1. Anticonvulsant data in mice injected i.p.
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flow rate of 0.3 ml/min, a gradient of 5–100% B over 10 min,
and an injection volume of 10 μl. The UPLC retention time
(tR) is given in minutes. Elemental analysis (C, H, and N) for
AS-1 was carried out by a micro method using the Vario EI III
elemental analyzer (Hanau, Germany). The results of elemen-
tal analyses were within ± 0.4% of the theoretical values. 1H
NMR and 13C NMR spectra were obtained in a JEOL 500
(JEOL USA, Inc., MA), in CDCl3 operating at 500 MHz
(1H NMR) and 126 MHz (13C NMR). Chemical shifts are
reported in δ values (ppm) relative to TMS δ = 0 (1H), as
internal standard. The J values are expressed in hertz (Hz).
Signal multiplicities are represented by the following abbrevi-
ations: s (singlet), br. s (broad singlet), d (doublet), q (quartet),
and m (multiplet).The detailed physicochemical and spectral
data for AS-1 are summarized in Table S1.
In Vivo Studies in Mice
Animals
All experiments were performed on male Swiss albino mice
(weighing 22–30 g) obtained from a licensed breeder.
Animals were housed in groups of 7–8 per cage under con-
trolled environmental conditions (temperature 21–24 °C, rel-
ative humidity 45–65%) at 12 h light–dark cycle (lights on at
6 a.m.) with free access to standard laboratory chow and tap
water. Before being used in the experiments, mice were
allowed to adapt to the laboratory conditions for at least
1 week. Housing and experimental procedures were conduct-
ed under the guidelines provided by the European Union
Directive of 22 September 2010 (2010/63/EU) and Polish
legislation concerning animal experimentation. All in vivo
procedures were approved by the Local Ethical Committee
in Lublin (License Nos. 16/2017 and 6/2019) and by the
Local Ethical Committee in Cracow (License No. 149/2018).
Treatment
For PTZ kindling, AS-1 was suspended in a 0.5% aqueous
solution of methylcellulose (tylose), while VPA and PTZ
were dissolved in normal saline. AS-1 and VPA were
injected repeatedly every 24 h for 33 consecutive days. In
studies assessing the acute effect of AS-1 on the seizure
threshold, AS-1 and VPA were given 30 min and 15 min
before the test, respectively. In isobolographic studies, AS-
1 (suspended in a 1% Tween 80) and VPA were adminis-
tered 30 min before s.c. injection of PTZ. All suspensions
and solutions were prepared freshly and administered in a
constant volume of 0.1 ml per 10 g of body weight. In all
experiments, AS-1 and VPA were injected i.p. Control an-
imals received vehicles only.
PTZ Kindling
For kindling induction, mice were repeatedly injected i.p.
with PTZ at a subconvulsive dose of 40 mg/kg on every
other day for 33 days (17 injections). After each PTZ
injection, mice were placed separately into transparent
cages for 30 min for behavioral observation to assign
an appropriate seizure score. Seizure severity was cate-
gorized according to a modified Racine’s scale [23] as
follows: stage 0, no change in behavior; stage 1, immo-
bility and ear and facial twitching; stage 2, myoclonic
jerks; stage 3, forelimb clonus; stage 4, clonic seizure
with rearing; stage 5, generalized clonic seizure with loss
of righting reflex; and stage 6, fore limb and hind limb
tonus. After each PTZ injection, the mean seizure sever-
ity score for each experimental group was calculated.
Non-kindled (control) mice were treated as kindled ani-
mals, except that they were injected with normal saline
instead of PTZ.
Twenty-four hours after the last PTZ injection (on day 34),
mice were subjected to the locomotor activity test, the elevat-
ed plus maze test, and the forced swim test. Forty-eight hours
after the last PTZ injection (on day 35) the i.v. PTZ seizure
threshold test was performed.
Experimental grouping for PTZ kindling was as follows:
(1) normal control, 0.5% tylose (33 injections) + saline (17
injections); (2) PTZ control, 0.5% tylose (33 injections) + PTZ
(17 injections); (3) positive control, VPA at 150 mg/kg (33
injections) + PTZ (17 injections); (4) AS-1 at 15 mg/kg (33
injections) + PTZ (17 injections); (5) AS-1 at 30 mg/kg (33
injections) + PTZ (17 injections); and (6) AS-1 at 60 mg/kg
(33 injections) + PTZ (17 injections).
Locomotor Activity Test
Spontaneous locomotor activity of mice was monitored using
the IR Actimeter system supported by SedaCom32 software
(Panlab/Harvard Apparatus, Barcelona, Spain) according to
the method described in detail elsewhere [13].
Elevated Plus Maze Test
The elevated plus maze test was used to assess the anxiety-like
behavior in kindled animal, as described in detail in our pre-
vious study [13].
Forced Swim Test
The forced swim test was used to assess the depressive-like
behavior in kindled animals. The procedure was performed as
described in detail elsewhere [13].
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i.v. PTZ Seizure Threshold Test
The timed i.v. PTZ test was used to evaluate the changes in
seizure threshold in both naïve and kindled mice. The exper-
imental procedure has been described in detail in our earlier
studies [13].
The 6-Hz Seizure Model (Current Intensity of 44 mA)
The 6-Hz-induced seizures were elicited by corneal
stimulation (6 Hz, 44 mA, 0.2 ms rectangular pulse
width, 3 s duration) using a constant-current device
(ECT Unit 57800; Ugo Basile, Gemonio, Italy) as de-
scribed previously [14]. A drop of 1% solution of lido-
caine hydrochloride was applied to the mouse corneas
before stimulation to provide local anesthesia and ensure
optimal current conductivity. After the electrical stimu-
lation, mice were gently released and observed for the
presence or absence of seizure activity, being character-
ized by immobility or stun posture associated with rear-
ing, forelimb clonus, twitching of the vibrissae, and
Straub tail. Mice resuming normal behavior within
10 s after stimulation were considered as protected
[24]. Subsequently, for compounds tested (AS-1 and
VPA), the ED50 value, which is defined as the dose of
a drug protecting 50% of animals against seizures, was
determined. To evaluate the ED50 value, three groups of
8 mice were injected with various doses of the tested
compound. The log-probit method was applied to statis-
tically determine the ED50 values, which are accompa-
nied by their respective 95% confidence limits [25].
s.c. PTZ-Induced Convulsions
The anticonvulsant activity of AS-1 and VPA against
PTZ-induced clonic seizures was determined after s.c. ad-
ministration of PTZ at a dose of 100 mg/kg [26, 27].
Following PTZ administration, mice were placed sepa-
rately in transparent Plexiglas cages (25 cm × 15 cm ×
10 cm) and observed for 30 min for the occurrence of
clonic seizures. Clonic seizure activity was defined as
the clonus of the whole body lasting for over 3 s, with
an accompanying loss of righting reflex. The number of
animals convulsing out of the total number of mice tested
was noted for each treatment regimen. The animals were
administered with increasing doses of VPA and AS-1, and
the anticonvulsant activity of each drug was evaluated as
the ED50 value (median effective dose of the drug, which
protects 50% of mice against clonic convulsions) calcu-
lated from the respective log-probit dose–response rela-
tionship line according to Litchfield and Wilcoxon [25].
The anticonvulsant activity of AS-1 alone was studied at
doses of 50–100 mg/kg, whereas that of VPA alone at
doses of 125–200 mg/kg against the clonic phase of the
PTZ-induced seizures in mice. Similarly, the anticonvul-
sant activity of a mixture of AS-1 with VPA was evaluat-
ed and expressed as ED50 mix, corresponding to the dose
of a mixture of both drugs required to protect 50% of
animals tested against PTZ-induced clonic convulsions.
Isobolographic Analysis of Interactions
Interactions between AS-1 and VPA against PTZ-induced sei-
zures were analyzed according to the methodology previously
detailed in earlier studies [26, 28, 29]. In the present study, the
isobolographic analysis comprised of 5 stages, as follows:
1. Determination of ED50 values for AS-1 and VPA
(administered separately) by means of log-probit lin-
ear regression analysis according to Litchfield and
Wilcoxon [25].
2. Calculation of purely additive ED50 add values ± SEM for
a mixture of the examined combination of AS-1 and VPA
at the fixed ratio 1:1. The ED50 add represents a total ad-
ditive dose of the drugs in the mixture, providing theoret-
ically a 50% protection against PTZ-induced seizures.
3. Experimental determination of the ED50 mix values ±
SEM for the combination of AS-1 and VPA at the fixed
ratio 1:1. ED50 mix is an experimentally determined total
dose of a mixture of two component drugs, administered
at a fixed ratio combination sufficient for the 50% protec-
tive effect against PTZ-induced seizures. To determine the
ED50 mix value, both drugs in the mixture (at proportion-
ally raised doses) were administered to the mice and a
dose–response relationship for the mixture was denoted
using Litchfield and Wilcoxon [25]’s log-probit method.
4. Statistical comparison of the experimentally derived ED50
mix values with their corresponding theoretically additive
ED50 add values was undertaken using the unpaired
Student’s t test, according to Tallarida [30].
5. Graphical illustration of the examined interactions as
isobolograms (i.e., simple forms of interaction
visualizations).
Chimney Test
The effects of AS-1, VPA, and their combination (at the
fixed ratio 1:1 from the PTZ test) on motor coordination
impairment were quantified with Boissier et al. [31]’s
chimney test. The pretreatment time for AS-1 and VPA
in the chimney test was identical to that of the PTZ test.
This experimental procedure has been described in detail
in our earlier studies [26, 32].
N-Benzyl-(2,5-dioxopyrrolidin-1-yl)propanamide (AS-1) with Hybrid Structure as a Candidate for a... 313
Grip Strength Test
The effects of AS-1, VPA, and their combination (at the fixed
ratio 1:1 from the PTZ test) on muscular strength in mice were
quantified by the grip strength test. The time before the com-
mencement of the grip strength test (after drug administration)
was identical to that of the PTZ test. This experimental proce-
dure has been described in detail in our earlier studies [26, 32].
Passive Avoidance Task
To assess potential acute adverse effects of AS-1, VPA, and
their combination (at the fixed ratio 1:1 from the PTZ test) on
the mice’s ability to acquire the task (learning) and to recall the
task (retrieval), the passive avoidance test was used as de-
scribed in detail in our previous study [26, 32].
EEG Recordings in Zebrafish Larvae
Animals
Adult zebrafish (Danio rerio) stocks of AB strain (Zebrafish
International Resource Center, Eugene, OR) were maintained
at standard aquaculture conditions, i.e., 28.5 °C, on a 14 h/10 h
light/dark cycle, lights on at 8 a.m. Fertilized eggs were col-
lected via natural spawning. Embryos were reared under con-
stant light conditions in embryo medium, i.e., Danieau’s buff-
er (1.5 mM HEPES, pH 7.6, 17.4 mM NaCl, 0.21 mM KCl,
0.12 mMMgSO4, and 0.18 mM Ca(NO3)2). All embryos and
larvae were kept in an incubator, at 28.5 °C. For EEG exper-
iments, larvae of 6 days post fertilization (dpf) were used. The
experiment was approved by the Norwegian Food Safety
Authority experimental animal administration’s supervisory
and application system (“Forsøksdyrforvatningen tilsyns- og
søknadssystem”; FOTS 18/106800-1).
Treatment
Substance AS-1 was dissolved in DMSO in order to make a
stock. Next, stock was diluted in embryo medium to reach a
maximum 1% w/v DMSO in final solution. Embryo medium
with an equivalent amount of DMSO was used as a vehicle
control. PTZ was purchased from Sigma-Aldrich and dis-
solved to 80 mM (4× stock) in embryo medium.
Toxicological Assessment
Maximum tolerated concentration was evaluated prior to fur-
ther experiments. Briefly, 4-dpf zebrafish larvae (n = 12/
group) were incubated with a range of AS-1 doses at
28.5 °C for 18 h. The following parameters were scored after
2 h and 18 h of exposure: touch response, posture, edema,
morphology, signs of necrosis, swim bladder, and heartbeat.
The dose of 5 mM was chosen for the EEG experiment.
EEG Discharge Assessment
A single 6-dpf zebrafish larvae were placed in a 48-well
plate (one larva per well) filled with 300 μl of vehicle or
300 μl of AS-1 solution. Subsequently, larvae were incu-
bated for 20 h, at 28.5 °C. After incubation, larvae were
exposed to vehicle or 20 mM PTZ for 5 min. Next, larvae
were immobilized in a thin layer of 2% low-melting-point
agarose and the glass electrode (resistance 1–5 MΩ) filled
with artificial cerebrospinal fluid (124 mM NaCl, 2 mM
KCl, 2 mM MgSO4, 2 mM CaCl2, 1.25 mM KH2PO4,
26 mM NaHCO3, 10 mM glucose) was placed into the
optic tectum (MultiClamp 700B amplifier, Digidata
1440A digitizer; Molecular Devices, San Jose, CA) [33,
34]. Single recordings for each larva were performed for a
period of 20 min. The discharges were analyzed according
to the duration of spiking paroxysms, and only those were
taken into account when the amplitude exceeded three
times the background noise. The data were analyzed with
the aid of Clampfit 10.2 software (Molecular Devices)
and custom-written program for R (Windows).
In Vitro Studies
Binding/Functional Studies
Binding/functional studies were performed commercially in
Cerep Laboratories (Poitiers, France) using testing procedures
described elsewhere. The general information is listed in
Table 4.
Electrophysiology
The influence of AS-1 (at a concentration of 100 μM) on fast
voltage-gated sodium channels was determined in prefrontal
cortex pyramidal neurons. Maximal currents were evoked
using rectangular voltage steps from the holding potential of
− 65 mV. Control recordings were conducted for 2 min, and
the investigated compounds were applied for 3 min. Currents
were normalized to control currents. The experimental proce-
dures used in this study adhered to the institutional and inter-
national guidelines on the ethical use of animals. Three-week-
old rats were decapitated under ethyl chloride anesthesia, and
their brains were removed. The methodology of slice prepa-
ration and slice preincubation was the same as in our previous
study [46]. Parts of the slices containing the prefrontal cortex
were mechanically and enzymatically dispersed, exactly the
same as in our previous study [46]. Prefrontal cortex pyrami-
dal neurons were visualized using a Nikon inverted micro-
scope. Pipette solution contained the following (in mM):
Kamiński et al.314
CsF (110), NaCl (7), EGTA (3), HEPES-Cl (10), MgCl2 (2),
and Na2ATP (4) at pH 7.4 and osmolarity of 290 mOsm. The
extracellular solution contained the following components (in
mM): NaCl (30), choline chloride (90), TEA-Cl (30), CaCl2
(2), MgCl2 (2), glucose (15), HEPES (10), LaCl3 (0.001), and
CdCl2 (0.4) at pH 7.4. Currents were recorded using an
Axopatch 1D amplifier and analyzed with pClamp software
(Molecular Devices). Patch pipettes had resistances between 4
and 5MΩ. After gigaseal formation, the electrode capacitance
was compensated. The patch membrane was ruptured by suc-
tion, and the membrane capacitance was compensated. The
access resistance was between 5 and 7MΩ. A series resistance
compensation of 80% was applied. The sodium currents were
leak subtracted. Recordings were performed at room temper-
ature. Voltage-gated potassium currents were not recorded be-
cause they were blocked by TEA-Cl in the extracellular solu-
tion. Moreover, there were no potassium ions in the intracel-
lular and extracellular solution. Voltage-gated calcium cur-
rents were blocked by cadmium and lanthanum ions in the
extracellular solution. Physiological holding potential (−
65 mV) was used throughout the study. The AS-1 compound
was applied to the whole bath.
In Vitro ADME-Tox Studies
The ADME-Tox parameters including permeability, met-
abolic stability, DDIs, and hepatotoxicity were carried
out as described previously [9–11, 13, 47]. The ability
of AS-1 to passively penetrate through the biological
membranes was estimated by Gentest Pre-coated
PAMPA Plate System (Corning, Tewksbury, MA) and
expressed as the permeability coefficient Pe. The human
metabolism of the compound AS-1 was studied using
human liver microsomes (HLMs) provided by Sigma-
Aldrich. The potential DDIs were predicted by lumines-
cent CYP3A4, CYP2D6, and CYP2C9 P450-Glo assays
(Promega, Madison, WI). The respective strong CYP’s
inhibitors, ketoconazole (KE, half maximal inhibitory
concentration (IC50) = 0.14 μM), quinidine (QD, IC50 =
0.01 μM), and sulfaphenazole (SE, IC50 = 0.08 μM),
were used as the references. The hepatic safety of AS-
1 was estimated here using hepatoma HepG2 cell
growth. The cells were seeded in a 96-well plate and
incubated in the presence of AS-1 at the concentration
range 0.1–100 μM. One micromolar of cytostatic drug
doxorubicin (DX) and 10 μM of mitochondrial toxin
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) were
used as the references.
Statistical Analysis
Most of the results were analyzed using one-way analysis
of variance (ANOVA) with Bonferroni’s post hoc test.
The EEG results were analyzed using two-way ANOVA,
with Bonferroni’s post hoc test, with the following fac-
tors: (1) for pretreatment, vehicle or AS-1, and (2) for
treatment, vehicle or PTZ. Statistical evaluation of
isobolographic interactions was performed by the use of
Student’s t test to detect the differences between the ex-
perimentally derived (ED50 mix) and theoretical additive
(ED50 add) values , according to Tal lar ida [30] .
Qualitative variables from the chimney test were com-
pared by using Fisher’s exact probability test. Median
retention times obtained in the passive avoidance task
were statistically evaluated using the Kruskal–Wallis non-
parametric ANOVA. Data from electrophysiological stud-
ies were compared with Student’s t test.
Differences among values were considered statistically sig-
nificant if p < 0.05. All statistical tests were performed using
GraphPad Prism (version 5.0) for Windows (GraphPad
Software, San Diego, CA).
Results
Anticonvulsant Activity in the 6-Hz (44 mA) Seizure
Model
Table 1 summarizes the quantitative data for AS-1 and
VPA. In this model of pharmacoresistant seizures, the
compound AS-1 revealed relatively potent activity. For
comparison, the ED50 value for the reference drug VPA
was obtained in the same experimental conditions.
Effect of Repeated Treatment with AS-1 on Seizure
Severity in the PTZ-Induced Kindling in Mice
Figure 2 shows the effect of repeated treatment with AS-
1 on the PTZ kindling progression in mice (one-way
ANOVA: F(4,64) = 9.66, p < 0.0001, on the 33rd day).
The repeated administration of PTZ at a subconvulsive
dose (40 mg/kg) on every alternate day for a total of 17
injections caused a gradual increase in the mean seizure
severity score in the control group (from 1.2 ± 0.1 after
the first PTZ injection to 4.4 ± 0.3 after the last PTZ
injection). Repeated treatment (a total of 33 injections)
with AS-1 at doses of 15 mg/kg, 30 mg/kg, and
60 mg/kg significantly suppressed kindling development
(p < 0.01 for AS-1 at 15 mg/kg and 30 mg/kg and
p < 0.001 for AS-1 at 60 mg/kg vs the PTZ-kindled con-
trol group). Likewise, VPA (positive control) at
150 mg/kg suppressed kindling progression (p < 0.001
vs the PTZ-kindled control group).
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Effect of Repeated Treatment with AS-1 on Locomotor
Activity in PTZ-Kindled Mice
No significant changes in spontaneous locomotor activity in
the PTZ-kindled control group (as compared to the non-
kindled control group) were observed (data not shown).
Repeated injection of AS-1 (15–60 mg/kg) or VPA
(150 mg/kg) did not affect locomotor activity in the kindled
mice as well (one-way ANOVA: F(5,77) = 1.06, p = 0.391).
Effect of Repeated Treatment with AS-1
in the Elevated Plus Maze Test in PTZ-Kindled Mice
No significant effect of PTZ kindling on animal performance
in the elevated plus maze test was observed (Fig. S1).
Moreover, repeated injection of AS-1 (15–60 mg/kg) or
VPA (150 mg/kg) did not produce any significant changes in
both the percentage of open arm entries and the percentage of
time spent in open arm entries in kindled animals (one-way
ANOVA: F(5,77) = 1.27, p = 0.286, for the percentage of
open arm entries, and F(5,76) = 2.90, p = 0.019, for the per-
centage of the time spent in the open arm entries).
Effect of Repeated Treatment with AS-1 on PTZ
Kindling–Induced Depression in Mice
Repeated PTZ injection on every alternate day produced
depressive-like behavior in mice, which was demonstrated
by an increase in the total immobility duration in the forced
swim test (p < 0.001 vs the non-kindled control group). VPA
injected repeatedly at a dose of 150 mg/kg slightly attenuated
the PTZ-induced behavioral despair and significantly de-
creased the immobility time in kindled animals (p < 0.05 as
compared to the kindled control group). However, repeated
injection of AS-1 (15–60 mg/kg) did not produce any signif-
icant changes in the total immobility duration in comparison
Fig. 2 Effect of AS-1 on kindling development in mice. Kindling was
induced by repeated injections of PTZ (40 mg/kg, i.p.) every 48 h for a
total of 17 injections. AS-1 and VPA were injected i.p. once daily for
33 days. Experimental groups consisted of 12–15 animals. Data are
expressed as means ± SEM. Statistical analysis: one-way ANOVA
followed by Bonferroni’s post hoc test. **p < 0.01, ***p < 0.001, as com-
pared to the kindled control group
Table 1 The quantitative data for AS-1 and VPA in the 6-Hz (44 mA) test in mice
Compound TPE (h) ED50 6-Hz (44 mA) (mg/kg)
a TD50 (mg/kg)
b PI (TD50/ED50)
c
AS-1 0.5 75.41 (63.60–89.42) 347.6 (132.7–288.6)d 4.6
VPA 0.5 183.1 (143.5–233.7) 430.7 (407.9–454.9)d 2.3
AS-1 and VPAwere injected i.p., 30 min before the tests. Values in parentheses are 95% confidence intervals determined by probit analysis
TPE = time to peak effect
a ED50 (6-Hz, psychomotor seizure test, 44 mA)
b TD50 (NT, acute neurological toxicity determined in the rotarod test)
c Protective index (TD50/ED50)
d Data from Kamiński et al. [10]
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to the PTZ-kindled control group (one-way ANOVA:
F(5,75) = 15.14, p < 0.0001; Fig. S2).
Effect of Repeated Treatment with AS-1
on the Seizure Threshold in the i.v. PTZ Test
in Kindled Mice
The effect of repeated AS-1 injection on the seizure thresholds
in the i.v. PTZ test in kindled mice is shown in Fig. 3 a–c (one-
way ANOVA: F(5,63) = 2.86, p = 0.022, for myoclonic
twitch; F(5,66) = 1.58, p = 0.178, for generalized clonus; and
F(5,59) = 1.43, p = 0.228, for forelimb tonus). PTZ-induced
kindling had no effect on thresholds for the first myoclonic
twitch, generalized clonic seizure, and forelimb tonus.
Repeated injection of AS-1 at the highest dose tested
(60 mg/kg) significantly increased the seizure threshold for
the first myoclonic twitch (p < 0.05 as compared to the non-
kindled control group). No changes in the thresholds for gen-
eralized clonus or forelimb tonus after repeated pretreatment
with AS-1 (15–60 mg/kg) were observed.
Effect of Acute Administration of AS-1 on the Seizure
Threshold in the i.v. PTZ Test in Naïve Mice
The effect of AS-1 administered acutely on the seizure thresh-
olds in the i.v. PTZ test in naïve mice is shown in Fig. 4 a–c
(one-way ANOVA: F(4,57) = 23.11, p < 0.0001, for myoclon-
ic twitch; F(4,57) = 11.90, p < 0.0001, for generalized clonus;
and F(4,53) = 15.62, p < 0.0001, for forelimb tonus). AS-1
injected at a dose of 15 mg/kg did not affect significantly the
thresholds for the first myoclonic twitch and generalized clo-
nus. However, AS-1 administered at doses of 30 mg/kg and
60 mg/kg raised the thresholds for both the first myoclonic
twitch (p < 0.01 and p < 0.001, respectively) and generalized
clonic seizure (p < 0.01 and p < 0.001, respectively). Acute
administration of AS-1 (15–60 mg/kg) did not affect the sus-
ceptibility of mice to the PTZ-induced forelimb extension.
Log-Probit Dose–Response Relationship Line Analysis
for AS-1 and VPA Against PTZ-Induced Clonic Seizures
in Mice
In the PTZ test, AS-1 was administered separately at the in-
creasing doses from 50 to 100 mg/kg. Subsequently, log-
probit transformation of the data allowed the determination
of the equation of dose–response relationship for AS-1 admin-
istered alone, which was y = 4.488x − 3.5682 [R2 = 0.8962]
(Fig. 5). The estimated ED50 value for AS-1 was 81.12 ±
10.39 mg/kg. With respect to VPA, the drug was given at
doses of 125 mg/kg, 150 mg/kg, and 200 mg/kg, and the
protection (in %) against PTZ-induced clonic seizures was
12.5%, 37.5%, and 62.5%, respectively. The equation of
dose–response relationship for VPAwas y = 7.0079x × 10.74
Fig. 3 Effect of repeated treatment with AS-1 on the threshold for the first
myoclonic twitch (panel a), generalized clonus (panel b), and forelimb
tonus (panel c) in the i.v. PTZ seizure test in kindledmice. PTZ (40mg/kg,
i.p.) was injected every 48 h for a total of 17 injections. AS-1 and VPA
were injected i.p. once daily for 33 days. Experimental groups consisted
of 8–15 animals. Data are expressed as means + SEM. Statistical analysis:
one-way ANOVA followed by Bonferroni’s post hoc test. *p < 0.05, as
compared to the non-kindled control group
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[R2 = 0.9586]. The ED50 for VPA was 176.22 ± 20.45 mg/kg
(Fig. 5).
Isobolographic Characteristic of the Interaction
Between AS-1 and VPA in PTZ-Induced Seizures
in Mice
The isobolographic analysis showed that a combination of
AS-1 and VPA at the fixed ratio of 1:1 displayed supra-
additive (synergistic) interactions against PTZ-induced sei-
zures in mice, because the experimentally denoted ED50 mix
(87.48 mg/kg) considerably differed from the theoretically
calculated ED50 add (128.67 mg/kg) (p < 0.05) (Table 2,
Fig. 6).
Effect of AS-1 Administered Alone
and in Combinations with VPA on Long-Term
Memory, Motor Coordination, and Skeletal Muscular
Strength in Mice
When AS-1 was co-administered with VPA at the fixed ratio
of 1:1, the motor coordination in mice was unaffected.
Furthermore, the studied combinations did not impair long-
term memory as determined in the passive avoidance task,
with the median retention time being 180 s. Similarly, this
combination had no effect on muscular strength, as assessed
by the grip strength test (Table 3). Moreover, AS-1 and VPA
administered alone at doses of 81.12mg/kg and 176.22mg/kg,
respectively, being their ED50 values from the PTZ test, did
not significantly affect long-term memory, muscular strength,
and motor performance in mice (Table 3).
Electrographic Discharge Assessment in Zebrafish
The EEG recordings from the optic tectum of zebrafish larvae
exposed to acute PTZ (20 mM) were performed to confirm the
anticonvulsant potential of AS-1 (5 mM). Exposure to AS-1
significantly reduced both numbers (Fig. 7a; two-way
ANOVA, pretreatment: F(1,32) = 8.02, p < 0.01; treatment:
F(1,32) = 31.99, p < 0.001; pretreatment × treatment interac-
tion: F(1,32) = 7.79, p < 0.01; n = 5–12/group) and total dura-
tion (Fig. 7b; two-way ANOVA, pretreatment: F(1,32) =
13.58, p < 0.001; treatment: F(1,32) = 28.98, p < 0.001; pre-
treatment × treatment interaction: F(1,32) = 12.55, p < 0.001;
n = 5–12/group) of epileptiform discharges in the zebrafish
brain in comparison to the control group which was incubated
in the vehicle. Additionally, AS-1 slightly decreased the mean
duration of events, but results did not reach statistical signifi-
cance (Fig. 7c; two-way ANOVA, pretreatment: F(1,32) =
5.58, p > 0.05; treatment: F(1,32) = 22.39, p < 0.01; pretreat-
ment × treatment interaction: F(1,32) = 4.52, p > 0.05; n = 5–
12/group).
Fig. 4 Effect of acute administration of AS-1 on the threshold for the
onset of first myoclonic twitch (panel a), generalized clonus (panel b),
and forelimb tonus (panel c) in the i.v. PTZ seizure threshold test in naïve
mice. AS-1 and VPAwere injected i.p. 30 min and 15 min before the test,
respectively. Experimental groups consisted of 10–14 animals. Data are
expressed as means + SEM. Statistical analysis: one-way ANOVA
followed byBonferroni’s post hoc test: **p < 0.01, ***p < 0.001, as com-
pared to the control group
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Binding/Functional Studies
In order to identify the plausible pharmacodynamics of the
compound AS-1, we performed binding/functional assays
for several molecular targets for anticonvulsants. Moreover,
bearing in mind cardiac safety, the influence of AS-1 on po-
tassium channel (hERG) was determined as well (Table 4).
Electrophysiology
AS-1 did not influence the maximal amplitude of sodium cur-
rents (1.0 in control and 0.93 ± 0.06 after the addition of the
tested compound, n = 6, p > 0.05). Example recordings of so-
dium currents and averaged results are shown in Fig. 8 a and b,
respectively.
In Vitro ADME-Tox Studies
The references used in the parallel artificial membrane perme-
ability assay (PAMPA) test included low-permeable
norfloxacin (NFX, Pe = 0.56 ± 0.01 × 10−6 cm/s) and well-
permeable caffeine (CFN, Pe = 15.1 ± 0.04 × 10−6 cm/s).
AS-1 showed permeability with calculated Pe = 9.8 ± 2.0 ×
10−6 cm/s (Table 5).
The UPLC analysis performed after 120 min of AS-1 in-
cubation with HLMs showed no presence of metabolites
(Fig. 9).
No significant effect of AS-1 on CYP3A4 and CYP2D6
activity was observed (Fig. 10a, b), whereas moderate
CYP2C9 inhibition was determined at the highest used doses
of 10 μM and 25 μM (Fig. 10c). For detail, see also data in
Table 5.
The slight but statistically significant effect of AS-1
(p < 0.05) on hepatoma HepG2 cells’ viability was observed
only at the highest concentration used of 100 μM. The refer-
ence toxins DX and CCCP decreased cells’ viability to ~ 40%
of control at 1 μM and 10 μM, respectively (Fig. 11, Table 5).
Discussion
In our previous study, AS-1 has been identified as a potent
broad-spectrum anticonvulsant agent. It produced a clear-cut
protective effect in three acute seizure tests in mice (i.e., MES,
s.c. PTZ, and 6-Hz at 32 mA) [10, 12]. With the aim of com-
pleting the anticonvulsant characterization of AS-1 in acute
seizure models in the current studies, we applied the 6-Hz test
at 44 mA. The 6-Hz model with 44 mA stimulus intensity has
been described as a useful tool in the identification of novel
compounds with potential efficacy against pharmacoresistant
seizures [17, 48]. In the previous paper, we demonstrated that
AS-1 protected mice against psychomotor seizures in the 6-Hz
test with 32mA stimulus intensity (a model of partial seizures)
with an effective dose value of 24.66 mg/kg [12]. In the pres-
ent study, the ED50 value was 75.41 mg/kg. It should be
stressed that in some cases, compounds may effectively block
seizures at a lower stimulus intensity of 32 mA but not at
44 mA. For LEV, the ED50 value is at least 50 times higher
Fig. 5 Log-probit dose–response relationship lines for AS-1 and VPA
administered alone in the mouse PTZ-induced clonic seizure model.
Doses of AS-1 and VPA were transformed in logarithms, whereas the
protective effects offered by the drugs administered alone against PTZ-
induced seizures were transformed in probits of response according to
Litchfield and Wilcoxon [25]. The equations of dose–response
relationship lines for AS-1 and VPA are presented on the graph, where
y is the probit of response, x is the logarithm to the base 10 of drug doses,
and R2 is the coefficient of determination. The test for parallelism of two
dose–response relationship lines revealed that both dose–response rela-
tionship lines were parallel
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at the 44 mA stimulus intensity versus the 32 mA [17].
Furthermore, as shown in Table 1, AS-1 revealed distinctly
more potent protection in the 6-Hz (44 mA) test and simulta-
neously offered better safety margin in the rotarod perfor-
mance test compared to VPA. These results may indicate the
potential utility of AS-1 in the treatment of refractory epilepsy
in humans.
In the subsequent studies, we aimed to investigate the an-
tiseizure effect of AS-1 in the PTZ-induced kindling model in
mice. The obtained results showed that the 33-day treatment
with AS-1 (at doses of 15 mg/kg, 30 mg/kg, and 60 mg/kg)
decreased the seizure severity score and thereby suppressed
kindling progression, which suggests that the tested com-
pound may possess the ability to prevent epilepsy develop-
ment. However, the observed effect could be related more to
the acute anticonvulsant activity of AS-1 rather than to its
possible antiepileptogenic-like properties. A different
experimental approach is required in order to ascertain wheth-
er AS-1 can suppress epileptogenesis.
PTZ is recognized as a noncompetitive GABAA receptor
antagonist. It binds to the picrotoxin-sensitive site of the
GABAA receptor complex and inhibits the GABA-evoked
chloride current [49]. Therefore, drugs effective in PTZ-
induced seizure models are generally considered to act via
GABAergic mechanisms. Kindling induced by PTZ was
shown to produce not only changes in the GABA-mediated
neurotransmission but also various alterations in glutamate
excitatory neurotransmission, mediated by both NMDA and
AMPA receptors, as well as some morphological changes in
the hippocampus, glucose hypometabolism, or antioxidant de-
fense systems [50, 51]. Noteworthy, a crucial role of synaptic
vesicle glycoprotein 2A (SV2A) in kindling development has
been also postulated [52]. Hence, several different mecha-
nisms could be responsible for the antiepileptogenic-like
Fig. 6 Isobologram showing the interaction between AS-1 and VPA
against PTZ-induced clonic seizures in mice. The ED50 value for AS-1
is plotted graphically on the x-axis, whereas the ED50 value of VPA is
plotted on the y-axis. The solid lines on the x- and y-axes represent the
95% confidence limits (CLs) for the drugs administered alone. The
straight line connecting these two ED50 values on the graph represents
the theoretical line of additivity for a continuum of 1:1 fixed dose ratios.
A = ED50 add; M = ED50 mix. All 95% CLs of A and M values are
presented horizontally and vertically in the shape of a cross. The exper-
imental ED50 mix values of the mixture of AS-1 + VPA (M) for the fixed
ratio of 1:1 are placed below the theoretical line of additivity, indicating
the supra-additive (synergistic) interactions; *p < 0.05
Table 2 Isobolographic analysis
of the interaction between AS-1
and VPA at the fixed-ratio com-
bination of 1:1 in the s.c. PTZ test
in mice
Combination ED50 add nadd ED50 exp nexp Alpha Interaction
AS-1 + VPA 128.67 ± 15.42 44 87.48 ± 12.75* 24 0.68 synergy
AS-1 and VPAwere injected i.p., 30 min before the test. Data are presented as ED50 values ± SEM. The clonic
phase of PTZ-induced seizures was produced by the s.c. injection of PTZ (100 mg/kg). The ED50 values were
either experimentally determined from the mixture of AS-1 and VPA (ED50 mix) or theoretically calculated from
the equation of additivity (ED50 add); n is the total number of animals used at those doses whose expected
anticonvulsant effects were ranged between 4 and 6 probits, denoted for the experimental mixture of drugs (nmix)
and theoretically calculated (n
add
) from the equation of additivity; alpha is the interaction index (ED50 mix/ED50 add)
*p < 0.05, versus the theoretically additive ED50 add value (unpaired Student’s t test with Welch correction)
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effects of AS-1 in the PTZ-induced kindling model. In our
previous report, in vitro radioligand binding studies revealed
that AS-1 exerted moderate affinity towards NMDA receptors
(antagonist radioligand) but it did not bind effectively to the
GABAA1 receptor α1, β2, and γ2 subunits [12]. Inhibition of
the GABAergic neurotransmission following PTZ administra-
tion leads to glutamatergic neuronal excitation, and possible
antagonistic interactions with NMDA receptors could be, at
least in part, responsible for the antiseizure properties of AS-1
in the PTZ kindling model. Nevertheless, this is a suggestion
only and further detailed studies are required to evaluate the
influence of AS-1 on glutamatergic neurotransmission.
Moreover, the tested compound (at high concentration) was
also shown to have moderate binding affinity for the L-type
Ca2+ channels (verapamil site) [12]. Although the L-type Ca2+
channels are not the main target for antiepileptic therapy, they
may also play a role in epileptogenesis [53].
It is widely known that the prevalence of depressive and
anxiety disorders is much higher in epileptic patients than in
general population. To evaluate the effect of AS-1 on these
two epilepsy-related comorbidities, the animals were subject-
ed to the elevated plus maze test and the forced swim test 24 h
after the last PTZ injection. No significant changes in the
anxiety-related response in the elevated plus maze test were
reported. However, we found that PTZ-induced kindling led
to the depressive-like behavior in mice, which is in agreement
with many previous reports [54–56]. Repeated injection of
AS-1 did not alleviate the kindling-induced behavioral despair
in mice. The animals’ performance in the elevated plus maze
test and the forced swim test was not affected by changes in
the spontaneous locomotor activity in mice. It is worth men-
tioning that in our former study, another hybrid compound—
KA-11 (1-(1-oxo-1-(4-(3-(trifluoromethyl)phenyl)piperazin-
1-yl)propan-2-yl)pyrrolidine-2,5-dione)—prevented the
depressive-like behavior caused by the PTZ-induced kindling
in mice [13].
In the next experiment, the effect of repeated AS-1 injec-
tion on the seizure threshold following PTZ kindling was
investigated. The timed i.v. PTZ seizure test was used as one
of the most sensitive methods for assessing seizure thresholds
in rodents. The test was performed 48 h after the last PTZ
injection in the kindling model. A slight increase in the seizure
threshold for myoclonic seizures was observed only in ani-
mals treated with AS-1 at the highest dose tested, i.e.,
60 mg/kg. No changes in the seizure threshold for generalized
clonic seizure and tonic seizure were noted. The obtained
results suggest that AS-1, in contrast to compound KA-11,
should not induce withdrawal hyperexcitability. In our previ-
ous study, KA-11 produced the withdrawal-induced reduction
in seizure susceptibility [13]. The acute effects of AS-1 on
seizure threshold in the i.v. PTZ test have not been previously
studied. Therefore, we also investigated the influence of AS-1
injected acutely on seizure susceptibility in naïve (i.e., non-
kindled) animals. AS-1 raised the threshold for both the first
myoclonic twitch and generalized clonus, but it did not in-
crease the threshold for forelimb tonus. Thus, it seems that
AS-1 was not able to slow down the progression of seizures
from generalized clonus with a loss of righting reflex to fore-
limb tonic extension. This is quite an unexpected result be-
cause AS-1 was shown to protect against tonic seizures in the
MES test [10]. PTZ-induced seizures are particularly sensitive
to compounds that act by enhancing the GABAergic neuro-
transmission, whereas the MES test is thought to be useful for
discovery of new anticonvulsants that inactivate sodium chan-
nels [57]. Therefore, it seems that AS-1 inhibits tonic seizures
rather by blocking sodium channels than by GABAergic
mechanisms. This issue warrants further investigation because
AS-1 did not inhibit voltage-gated sodium currents in rat cor-
tical neurons. It did, however, bind to the neuronal sodium
channels (site 2) but only at the very high concentration of
500 μM [12].
As previously mentioned, AEDs enhancing GABA-
mediated inhibition in the brain are effective in the sup-
pression of clonic seizures in rodents after the s.c. injec-
tion of PTZ [27, 58]. Thus, the PTZ test is considered as a
model of myoclonic and absence seizures in epileptic
Table 3 Effects of AS-1, VPA,
and their combinations on long-
term memory, skeletal muscular
strength, and motor coordination
in mice
Treatment (mg/kg) Retention time (s)a Muscular strength (g)b Motor coordination (%)c
Control 180 (156; 180) 102.1 ± 2.6 0
AS-1 (81.12) + vehicle 180 (146; 180) 99.9 ± 2.2 0
VPA (176.22) + vehicle 180 (180; 180) 104.7 ± 2.8 12.5
AS-1 (27.6) + VPA (59.9) 180 (160; 180) 104.2 ± 4.7 0
Results are presented as follows: (a) median retention times (in seconds; with the 25th and 75th percentiles in
parentheses) from the passive avoidance task, assessing long-term memory in mice; (b) mean grip strengths (in
grams ± SEM) from the grip strength test, assessing muscular strength in mice; and (c) percentage of animals
showing motor coordination impairment in the chimney test in mice. AS-1 and VPAwere injected i.p., 30 min
before the tests. Each experimental group consisted of 8 animals. Statistical analysis of data from the passive
avoidance task was performed with the Kruskal–Wallis nonparametric ANOVA test followed by Dunn’s post hoc
test, whereas those from the grip strength test were analyzed with one-way ANOVA followed by Bonferroni’s
post hoc test. Fisher’s exact probability test was used to analyze the results from the chimney test
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patients [59, 60]. Bearing in mind the antiseizure proper-
ties of AS-1 in the PTZ-induced kindling model in mice
in the subsequent studies, we investigated its interaction
with VPA using the PTZ as proconvulsant agent. Results
from isobolographic analysis indicated that the combina-
tion of AS-1 and VPA, at a fixed ratio of 1:1, exerted a
supra-additive (synergistic) interaction against PTZ-
induced clonic seizures in mice. This is probably an out-
come of the mechanisms of action of both drugs. One of
the mechanisms of action for VPA is GABA levels in-
creasing in the whole brain and enhancing GABAergic
activity [61, 62]. We can speculate that AS-1 also acts
through the GABA system, so the combination of both
VPA and AS-1 results in a statistically significant de-
crease of drug doses leading to a supra-additive effect. It
should be emphasized that AEDs producing a synergistic
interaction in isobolography may prove advantageous in
the clinical settings mainly due to the reduction of drugs’
doses. Furthermore, results from the behavioral studies
showed that AS-1 and VPA administered alone and in
combination at a fixed ratio of 1:1 (at doses correspond-
ing to their ED50 values from the s.c. PTZ test) did not
cause any disturbances in the chimney, passive avoidance,
and grip strength tests in mice. The lack of acute adverse
effects results from the reduction of AS-1 and VPA doses,
which suggests that it would be a safe combination in
further more advanced clinical studies.
In our previous paper, we proved the efficacy of AS-1 in
different acute seizure tests in mice. To complement our ob-
servation, herein, we assessed its activity in larval zebrafish by
means of EEG recordings. We found out that the
preincubation of larval zebrafish with AS-1 decreased the
number and cumulative duration of EEG discharges induced
by acute PTZ. This proconvulsant in larval zebrafish induces a
number of behavioral changes, starting with burst swimming
and culminating in tonic–clonic convulsions, resembling epi-
leptic seizures in mammals [34, 63, 64]. At the EEG level,
exposure to PTZ induces frequent, recurrent ictal-like dis-
charges [33, 65]. To date, the zebrafish PTZ assay has been
validated and extensively characterized using commercially
available AEDs [33, 66], while obtained results have been
proved to translate well to rodent models [34, 65, 67, 68].
In our previous study, we did not manage to explain the
potential mechanism of action for AS-1 satisfactorily [12]. We
noted only a moderate binding to sodium channel (site 2),
verapamil site of the L-type Ca2+ channel, and NMDA recep-
tor, however only at the very high concentration of 100 μMor
500 μM (for details, see Table 4). Therefore, on the basis of
these data, it is hard to hypothesize about clear and certain
pharmacodynamics of AS-1. To extend the in vitro character-
ization of AS-1 that could potentially define the plausible
mechanism of action, we decided herein to investigate its in-
fluence on the L-type Ca2+ channel (diltiazem site), GABA
Fig. 7 Electrophysiological recordings from the optic tectum of larvae
pre-exposed to vehicle or AS-1. Results are presented as the number of
epileptiform events during 20 min (a), the cumulative duration of epilep-
tiform events during 20 min (b), and the mean duration of the event (c).
Experimental groups consisted of 5–12 animals. Statistical analysis: two-
way ANOVA followed by Bonferroni’s post hoc test. **p < 0.01, ***p
< 0.001, as compared to the vehicle + vehicle group; ^^^p < 0.001, as
compared to the vehicle + PTZ group
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transporter, and the newest and currently attractive targets for
anticonvulsants such as TRPV1 (receptor potential cation
channel vanilloid type 1 ion channel) and cannabinoid CB1
receptors [69, 70] (Table 4). Notably, the interaction between
TRPV1 and CB1 receptors is crucial for the pharmacodynam-
ics of cannabidiol, which is currently used in children with
pharmacoresistant epilepsy, such as Dravet or Lennox–
Gastaut syndromes [69, 71, 72]. As a result, in the binding/
functional studies, AS-1 did not interact with the L-type Ca2+
channel (diltiazem site), GABA transporter, or TRPV1 and
CB1 receptors at a high concentration of 100 μM. Thus, on
the basis of the previous and current binding and/or functional
assays, the mechanism of action for AS-1 remains undefined.
We can only state that the broad-spectrum anticonvulsant
Table 4 In vitro binding/functional assays for AS-1
Source Ref.
% inhibition of control-specific binding
(concentration in μM)
Binding studies
Na+ channel (site 2)a Rat cerebral cortex 15.9 (100)
56.0 (500)*
[35]
L-type Ca2+ (dihydropyridine site, antagonist radioligand)a Rat cerebral cortex − 14.8 (100) [36]
L-type Ca2+ (verapamil site, antagonist radioligand)a Rat cerebral cortex 15.0 (100)
45.0 (500)
[37]
L-type Ca2+ (diltiazem site, antagonist radioligand) Rat cerebral cortex 10.2 (100) [38]
N-type Ca2+ (antagonist radioligand)a Rat cerebral cortex 0.2 (100) [39]
NMDA (antagonist radioligand)a Rat cerebral cortex 15.0 (100)
35.0 (200)
[40]
GABAA1 (α1β2γ2) (agonist radioligand)
a Rat cerebral cortex − 18.3 (100) [41]
GABA transporter (antagonist radioligand) Rat cerebral cortex 2.4 (100) [42]
Potassium channel (hERG) Human recombinant (HEK-293 cells) 0.8 (100) [43]
% inhibition of control agonist/antagonist
response (concentration in μM)
Functional studies
TRPV1 (VR1) (h) (antagonist effect) Human recombinant (CHO cells) 4.3 (100) [44]
CB1 (h) (agonist effect) Human recombinant (CHO cells) − 6.8 (100) [45]
CB1 (h) (antagonist effect) Human recombinant (CHO cells) 5.6 (100) [45]
a Data from Rapacz et al. [12]
*Results showing an inhibition higher than 50% are considered to represent significant effects of the test compounds, results showing an inhibition
between 25 and 50% are indicative of weak effect, and results showing an inhibition lower than 25% are not considered significant and mostly
attributable to the variability of the signal around the control level
Fig. 8 The influence of AS-1 on
fast voltage-gated sodium current
in prefrontal cortex pyramidal
neurons. (a) Example recordings
of maximal voltage-gated sodium
currents in the control and in the
presence of AS-1. Currents were
evoked by rectangular voltage
steps to − 10 mV, as shown above
the current traces. (b) Averaged
normalized maximal sodium cur-
rent amplitudes in the control and
in the presence of AS-1.
Statistical analysis: Student’s t test
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activity in the acute and kindling models of epilepsy observed
for AS-1 in the preclinical studies most likely reflects its mul-
tiple sites of action. The profile of anticonvulsant activity may
suggest among others the modulation of postsynaptic AMPA
receptors’ function as well as the inhibition of glutamate re-
lease from the presynaptic neurons in the hippocampus (e.g.,
through the influence on SV2A protein of synaptic vesicles or
inhibition of presynaptic voltage-gated Ca2+ channels)
[73–78]. In the aim of determination of AS-1 interaction with
other binding sites on sodium channels (beyond site 2, see
Table 4), we studied its influence on sodium currents in rat
prefrontal cortex pyramidal neurons using the patch clamp
technique. The results obtained indicate that AS-1 does not
interact with fast voltage-gated sodium channels at a concen-
tration of 100 μM.
The ADME-Tox parameters evaluated for the compound
AS-1 by in vitro methods included permeability, metabolic
stability, DDIs, and hepatotoxicity. The PAMPAwas used here
to determine the passive diffusion of AS-1 through artificial
membrane, which imitates the cellular one. The passive trans-
port is a very important parameter to be determined at the early
stage of drug discovery process, as it is the predominant mech-
anism for absorption of most commercial drugs [79]. As a
result, AS-1 showed very good ability to passive diffusion in
comparison to the highly permeable reference caffeine. The
metabolic stability is another important parameter, since the
structures that are highly active in vitro may be susceptible to
metabolism in the body and not reach the molecular target
[79]. In our study, no phase I metabolites were observed at
the UPLC spectra after the 120-min incubation with HLMs,
indicating an excellent metabolic stability of the compound
AS-1. Many DDIs can occur when two drugs are co-
administered and compete for the same enzyme. Most of the
detected DDIs were mediated by the cytochrome P450 family
of enzymes [79]. Thus, during this study, the effect of AS-1 on
CYP3A4, 2D6, and 2C9 activity was investigated and com-
pared to the respective inhibitors. Notably, the aforementioned
CYP isoforms are responsible for the metabolism of approx-
imately 70% of all marketed drugs [79]. No significant effect
of AS-1 on CYP3A4 and CYP2D6 activity was observed,
whereas moderate CYP2C9 inhibition was found at the
highest used doses of 10 μM and 25 μM. The obtained results
indicated a low risk of potential DDIs after potential drug co-
administration with AS-1. In our previous study [12], AS-1
was incubated with HepG2 cells for 24 h and showed a weak,
statistically significant toxic effect only at the highest used
dose of 100 μM. To exclude the potential long-term hepato-
toxic effect, AS-1 incubation time with cells was prolonged
Table 5 In vitro ADME-Tox parameters of AS-1
Assay Result
Pe (10−6 cm/s ± SD) 9.8 ± 2.0a
Phase I metabolism in human No metabolites found
CYP3A4 activity* 96.9 ± 0.4a
CYP2D6 activity* 104.4 ± 0.5a
CYP2C9 activity* 67.0 ± 3.6a
HepG2 viability** 82.3 ± 6.5a
*Percentage of control ± SD at 10 μM
**Percentage of control ± SD at 100 μM
aTested in at least 3 repetitions
Fig. 9 UPLC spectra of the reaction mixture after the 120-min incubation of AS-1 with HLMs
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here up to 72 h. The slight but statistically significant effect on
cells’ viability was observed only at the highest used dose of
100 μM and confirmed our previous data [12]. Thus, taking
into account these both independent studies, the compound
AS-1 showed a very low risk of potential hepatotoxicity.
Conclusions
The results of the current studies proved that N-benzyl-(2,5-
dioxopyrrolidin-1-yl)propanamide (AS-1) may be regarded as
a novel wide-spectrum anticonvulsant agent. We showed that
AS-1 produced antiseizure effect in the PTZ kindling model.
Noteworthy, this molecule reveled also protection in the 6-Hz
(44 mA) seizure test, which is recognized as an animal model
of human drug-resistant seizures. The comprehensive pharmaco-
logical investigation described herein showed more potent anti-
convulsant protection and clearly better safety profile for AS-1
versus VPA which belongs to the most frequently prescribed
AEDs, as it is effective in case of different types of epilepsies.
The isobolographic analysis indicated the supra-additive
(synergistic) interaction of AS-1 and VPA in the PTZ-induced
clonic seizures in mice, notably without increasing disturbances
in the chimney, passive avoidance, and grip strength tests in
mice. Thus, it is postulated that AS-1 + VPA in combination
appeared to be beneficial and safe regarding the advanced clinical
investigation. The high safety profile of AS-1was also confirmed
in the in vitro studies, as it showed no significant influence on the
function of CYP3A4/CYP2D6 activity, only moderate inhibition
of CYP2C9 at a concentration of 10 μM, and no hepatotoxic
properties in HepG2 cells (concentration of 10 μM).
Unfortunately, the in vitro binding and functional studies, as well
as patch clamp technique, did not provide firm evidence on the
plausible mechanism of action for AS-1.
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Fig. 10 The effect of the respective inhibitor and compound AS-1 on the
CYP3A4 (a), CYP2D6 (b), and CYP2C9 (c) activity
Fig. 11 The effects of AS-1 and reference toxins (DX = doxorubicin;
CCCP = carbonyl cyanide 3-chlorophenylhydrazone) on the hepatoma
HepG2 cell line viability. Statistical analysis: one-way ANOVA followed
by Bonferroni’s post hoc test. *p < 0.05, ***p < 0.001
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